Aggressive Lymphoma after CD19 CAR T-Cell Therapy suggested by Vivek Subbiah
Vivek Subbiah shared a post on X:
“Aggressive Lymphoma after CD19 CAR T-Cell Therapy clonal hematopoiesis had contributed to lymphomagenesis.”
Aggressive Lymphoma after CD19 CAR T-Cell Therapy
Authors: Guido Kobbe, et al.
Source: Vivek Subbiah/X
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023